From: The future of viral hepatitis testing: innovations in testing technologies and approaches
Areas of activity | Key deliverables |
---|---|
Enable platform polyvalence and HCV/HIV integration through supporting DBS protocol development, regulatory approval and policy change | - Evaluation of DBS sampling for centralized EIA and RNA assays - Use of existing HIV lab infrastructure for introducing HCV testing - Demonstrate service delivery advantages of one step sampling (EIA/ RNA) using DBS |
Expand use of HCV core antigen assays | - Compare cAg against gold standard as test of cure using current lab-based technology - Evaluate feasibility, cost, cost-effectiveness and impact of cAg assay as one testing approach in high prevalence populations - Accelerate development of POC cAg devices |
Enable decentralization of HCV services | - Integration of HCV/TB/HIV assays in decentralized settings - Demonstrate feasibility of HCV testing and treatment in different decentralized settings - Costing of different testing/ treatment pathways across countries and sites - Evaluate acceptability and cost-effectiveness of finger stick blood sample collection - Accelerate development of POC molecular devices |
Increase access to quality-assured HCV RDTs | - Piloting quality-assured RDTs using capillary blood in high risk groups - Assess market and feasibility of HCV ST and/or combo test among different populations |